Article history: Received 8 May 2017 Received in revised form 9 October 2017 Accepted 9 October 2017 Available online xxxx Antipsychotic medications are associated with weight gain and adverse metabolic effects that complicate the treatment and management of schizophrenia. Olanzapine (OLZ) in particular is associated with significant weight gain and adverse metabolic effects. The present Phase 1, proof of concept, multicenter, randomized, double-blind, placebo-controlled study investigated the safety and effect on weight of a combination of OLZ (10 mg) and the opioid modulator samidorphan (SAM; 5 mg) in comparison to OLZ alone in healthy, male normal weight volunteers. Altogether, 106 male subjects with stable body weight and BMI 18-25 kg/m 2 were randomized to OLZ alone, OLZ + SAM, SAM alone, or placebo in a 2:2:1:1 ratio. The primary efficacy endpoint, mean (SD) body weight change from baseline to last assessment in the 3-week treatment period, was significantly less for OLZ + SAM vs. OLZ alone subjects [+2.2 (1.4) kg vs. +3.1 (1.9) kg; respectively; p = 0.02]. In contrast, there was no significant difference in weight from baseline for either SAM or placebo [+0.1 (1.0) kg and +0.8 (1.4) kg, respectively]; p = 0.09. Overall, OLZ + SAM compared to OLZ alone had similar safety and tolerability. In addition, less nausea was observed in subjects given OLZ + SAM compared to SAM alone. Thus, OLZ + SAM may offer effective treatment of schizophrenia with less weight gain and metabolic risk. Additional research exploring additional doses over longer durations in psychiatric populations is warranted.
Introduction
Nearly all antipsychotic medications are associated with weight gain and significant adverse metabolic effects including Type 2 Diabetes Mellitus (T2DM), hyperglycemia, and hyperlipidemia (Bak et al., 2014; Correll et al., 2011; De Hert et al., 2011b; Leucht et al., 2012; Liposits and Bohn, 1993) . This adverse effect cluster presents an obstacle in the treatment and management of patients with schizophrenia or bipolar disorder, and limits patient adherence to medication and consequently adversely impacts treatment outcomes. Therefore, a medication that is effective in treating symptoms of schizophrenia and bipolar disorder with an improved safety and tolerability profile is a much needed addition to the therapeutic armamentarium.
Olanzapine (OLZ) is regarded as one of the most effective treatments for schizophrenia and bipolar disorder (Cipriani et al., 2011; Leucht et al., 2013) , but concerns with weight gain and adverse metabolic effects have affected physician prescribing and patient adherence to OLZ treatment (De Hert et al., 2011a; Lieberman et al., 2005) . However, several studies have demonstrated that patients actually stay on OLZ for longer periods of time and that it has a lower discontinuation rate in comparison with other antipsychotics. For instance, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study (Lieberman et al., 2005) demonstrated that patients stayed on OLZ significantly longer than other antipsychotics (median time-to-discontinuation: 9.2 months vs. 3.5 to 5.6 months for comparators, with hazard ratios ranging from 0.63 to 0.78). The CATIE study specifically noted that OLZ had the "lowest rate of discontinuation due to lack of efficacy", as well as a "greater reduction in psychopathology, longer duration of successful treatment", and "lower rate of hospitalizations for an exacerbation of schizophrenia" compared with other approved antipsychotic drugs. Despite these benefits of OLZ, utilization has decreased due to the growing concern and awareness of OLZ-associated weight gain and metabolic dysregulation (Nasrallah and Newcomer, 2004) . Indeed, in the CATIE study discontinuation from OLZ was primarily due to weight gain or metabolic effects (Lieberman et al., 2005) . 
